Background: The serum & glucocorticoid inducible kinase isoform SGK3 is a powerful regulator of several transporters, ion channels and the Na+/K+ ATPase. Targets of SGK3 include the ubiquitin ligase Nedd4-2, which is in turn a known regulator of the voltage gated K+ channel Kv1.5 (KCNA5). The present study thus explored whether SGK3 modifies the activity of the voltage gated K+ channel KCNA5, which participates in the regulation of diverse functions including atrial cardiac action potential, activity of vascular smooth muscle cells, insulin release and tumour cell proliferation. Methods: cRNA encoding KCNA5 was injected into Xenopus oocytes with and without additional injection of cRNA encoding wild-type SGK3, constitutively active S419DSGK3, inactive K191NSGK3 and/or wild type Nedd4-2. Voltage gated K+ channel activity was quantified utilizing dual electrode voltage clamp. Results: Voltage gated current in KCNA5 expressing Xenopus oocytes was significantly enhanced by wild-type SGK3 and S419DSGK3, but not by K191NSGK3. SGK3 was effective in the presence of ouabain (1 mM) and thus did not require Na+/K+ ATPase activity. Coexpression of Nedd4-2 decreased the voltage gated current in KCNA5 expressing Xenopus oocytes, an effect largely reversed by additional coexpression of SGK3. Conclusion: SGK3 is a positive regulator of KCNA5, which is at least partially effective by abrogating the effect of Nedd4-2.

The serum & glucocorticoid inducible kinase isoform SGK3 up-regulates diverse transporters [1,2,3,4,5], the Na+/K+ ATPase [6] and channels [4,5,7,8] including Ca2+ channels [7,9] and voltage-gated K+ channels [4,10,11]. The cardiac channels regulated by SGK3 include KV11.1 channels, which play an important role in the repolarization phase of the cardiac action potential [11]. The related kinase SGK1 has previously been shown to regulate the voltage gated K+ channel KCNA5 [12], a channel implicated in a variety of functions including the proliferation and migration of normal and tumour cells [13,14], repolarization in cardiac atria [15,16,17,18], pulmonary artery smooth muscle cell activity [19,20], and insulin release [12].

KCNA5 is a target of the ubiquitin ligase Nedd4-2 , which is in turn a target of SGK isoforms [21]. Along those lines, SGK1 is effective by inhibiting Nedd4-2 and thus increases KCNA5 protein abundance in the cell membrane [22]. Conversely Nedd4-2 decreases the KCNA5 protein abundance in the cell membrane and ablation of the SGK1 phosphorylation sites in the Nedd4-2 protein significantly blunted the effect of the kinase on KCNA5 protein abundance in the cell membrane [22].

The present study explored, whether SGK3 similarly modifies the activity of KCNA5. To this end, KCNA5 was expressed in Xenopus oocytes without or with additional expression of wild type SGK3, constitutively active S419DSGK3, or inactive K191NSGK3. Additional experiments were performed in oocytes expressing wild type Nedd4-2. The voltage gated K+ current was determined in those oocytes by dual electrode voltage clamp.

Ethical Statement

All experiments conform with the ‘European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes' (Council of Europe No 123, Strasbourg 1985) and were conducted according to the German law for the welfare of animals and the surgical procedures on the adult Xenous laevis frogs were reviewed and approved by the respective government authority of the state Baden-Württemberg (Regierungspräsidium) prior to the start of the study (Anzeige für Organentnahme nach §36).

Constructs

Constructs encoding mouse wild-type KCNA5 [23,24], wild type SGK3 [25], constitutively active S419DSGK3 [26], inactive K191NSGK3 [26] and wild type Nedd4-2 [2] were used for generation of cRNA as described previously [27,28,29].

Voltage clamp in Xenopus oocytes

Xenopus oocytes were prepared as previously described [30,31,32]. 2.5 ng cRNA encoding KCNA5 and 10 ng of cRNA encoding wild-type SGK3, constitutively active S419DSGK3 , inactive K191NSGK3 or wild type Nedd4-2 were injected on the same day after preparation of the oocytes. Where indicated oocytes expressing KCNA5 without or with additional expression of SGK3 were treated with 1 mM ouabain for 10 minutes before measurement and ouabain was superfused during the measurement. KCNA5 activation kinetics were determined from peak current quantification during a -60 mV test-pulse following 200ms pre-pulses from -50 to +50 mV. Determination of KCNA5 inactivation was based on a two-pulse protocol containing a 1 s pre-pulse from potentials of -60 to +40 mV followed by a 200 ms test-pulse to +70 mV. Normalized test-pulse peak currents were plotted versus pre-pulse voltage and fitted to the Boltzmann equation yielding V1/2 for channel activation and inactivation. The oocytes were maintained at 17°C in ND96A, a storage solution containing (in mM): 88.5 NaCl, 2 KCl, 1 MgCl2, 1.8 CaCl2, 5 HEPES (pH 7.5), 5 sodium pyruvate (C3H3NaO3), Gentamycin (100 mg/l), Tetracycline (50 mg/l), Ciprofloxacin (1.6 mg/l), Theophylline (90 mg/l) [33,34,35,36]. The voltage clamp experiments were performed at room temperature 3 days after the first injection [37,38,39]. KCNA5 channel currents were elicited every 20 s with 2 s pulses from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. The data were filtered at 1 kHz and recorded with a Digidata A/D-D/A converter (1322A Axon Instruments) and Clampex 9.2 software for data acquisition and analysis (Axon Instruments) [40,41,42]. The control superfusate (ND96B) contained (in mM): 93.5 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 2.5 NaOH and 5 HEPES, pH 7.4. The flow rate of the superfusion was approx. 20 ml/min, and a complete exchange of the bath solution was reached within about 10 s [43,44].

Statistical analysis

Data are provided as means ± SEM, n represents the number of oocytes investigated. As different batches of oocytes may yield different results, comparisons were always made within a given oocyte batch. All voltage clamp experiments were repeated with at least 3 batches of oocytes; in all repetitions qualitatively similar data were obtained. Data were tested for significance using ANOVA (Tukey test or Kruskal-Wallis test) or t-test, as appropriate. Results with p < 0.05 were considered statistically significant.

The present study explored whether the serum & glucocorticoid inducible kinase isoform SGK3 participates in the regulation of the voltage gated K+ channel KCNA5. To this end, cRNA encoding KCNA5 was injected into Xenopus oocytes with or without additional injection of cRNA encoding wild-type SGK3 and the peak K+ current (IK) quantified in those oocytes utilizing dual electrode voltage clamp. As illustrated in Fig. 1, IK was negligible in water-injected oocytes indicating that the oocytes did not express appreciable voltage gated K+ channels. In contrast, sizable voltage gated K+ currents were observed in Xenopus oocytes expressing KCNA5. The additional coexpression of wild-type SGK3 was followed by a significant increase of IK. As illustrated in Fig. 2, expression of wild-type SGK3 increased the K+ conductance and did not shift the KCNA5 kinetics.

Fig. 1

Coexpression of wild type SGK3 increases the K+ current in KCNA5-expressing Xenopus oocytes. A: Representative original tracings showing currents in Xenopus oocytes injected with water (a), expressing KCNA5 alone (b) or expressing KCNA5 with additional coexpression of wild-type SGK3 (c). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 6 - 26) of the normalized depolarization-induced KCNA5 peak current (I) as a function of the potential difference across the cell membrane (V) in Xenopus oocytes injected with water (black squares) or expressing KCNA5 without (white circles) or with (black circles) additional coexpression of wild-type SGK3. Peak currents were normalized to the mean peak current at +50 mV in Xenopus oocytes injected with cRNA encoding KCNA5 alone. C: Arithmetic means ± SEM (n = 6 - 26) of the normalized KCNA5 -peak current at +50 mV in Xenopus oocytes injected with water (dotted bar), or expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Fig. 1

Coexpression of wild type SGK3 increases the K+ current in KCNA5-expressing Xenopus oocytes. A: Representative original tracings showing currents in Xenopus oocytes injected with water (a), expressing KCNA5 alone (b) or expressing KCNA5 with additional coexpression of wild-type SGK3 (c). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 6 - 26) of the normalized depolarization-induced KCNA5 peak current (I) as a function of the potential difference across the cell membrane (V) in Xenopus oocytes injected with water (black squares) or expressing KCNA5 without (white circles) or with (black circles) additional coexpression of wild-type SGK3. Peak currents were normalized to the mean peak current at +50 mV in Xenopus oocytes injected with cRNA encoding KCNA5 alone. C: Arithmetic means ± SEM (n = 6 - 26) of the normalized KCNA5 -peak current at +50 mV in Xenopus oocytes injected with water (dotted bar), or expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Close modal
Fig. 2

Coexpression of wild type SGK3 increases the K+ conductance but does not significantly modify channel kinetics in KCNA5-expressing Xenopus oocytes. A. Arithmetic means ± SEM (n = 6 - 26 ) of the conductance analyzed between 20 mV and 50 mV in Xenopus oocytes injected with water (dotted bar), or expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. B. KCNA5 kinetics in Xenopus oocytes expressing KCNA5 without (white circles) or with (black circles) additional coexpression of wild-type SGK3. KCNA5 activation kinetics was determined from peak current quantification during a -60 mV test-pulse following 200ms pre-pulses from -50 to +50 mV. Determination of KCNA5 inactivation was based on a two-pulse protocol containing a 1 s pre-pulse from potentials of -60 to +40 mV followed by a 200 ms test-pulse to +70 mV. *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone.

Fig. 2

Coexpression of wild type SGK3 increases the K+ conductance but does not significantly modify channel kinetics in KCNA5-expressing Xenopus oocytes. A. Arithmetic means ± SEM (n = 6 - 26 ) of the conductance analyzed between 20 mV and 50 mV in Xenopus oocytes injected with water (dotted bar), or expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. B. KCNA5 kinetics in Xenopus oocytes expressing KCNA5 without (white circles) or with (black circles) additional coexpression of wild-type SGK3. KCNA5 activation kinetics was determined from peak current quantification during a -60 mV test-pulse following 200ms pre-pulses from -50 to +50 mV. Determination of KCNA5 inactivation was based on a two-pulse protocol containing a 1 s pre-pulse from potentials of -60 to +40 mV followed by a 200 ms test-pulse to +70 mV. *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone.

Close modal

Further experiments explored, whether the effect of wild-type SGK3 on KCNA5 was modified by mutations affecting kinase activity. As illustrated in Fig. 3, the effect of wild type SGK3 was mimicked by the constitutively active S419DSGK3, but not by the inactive K191NSGK3, i.e. coexpression of S419DSGK3 but not of K191NSGK3 significantly increased IK in KCNA5 expressing oocytes.

Fig. 3

The effect of wild type SGK3 on KCNA5 was mimicked by constitutively active S419DSGK3 but not by inactive K191NSGK3. A: Representative original tracings showing currents in Xenopus oocytes expressing KCNA5 alone (a), expressing KCNA5 together with wild-type SGK3 (b), expressing KCNA5 together with constitutively active S419DSGK3 (c), or expressing KCNA5 with inactive K191NSGK3 (d). B: Arithmetic means ± SEM (n = 17) of the normalized KCNA5 -peak current at +50 mV in Xenopus laevis oocytes expressing KCNA5 alone (white bar) or expressing KCNA5 together with wild type SGK3 (black bar), with constitutively active S419DSGK3 (dark grey bars), or with inactive K191NSGK3 (light grey bar). ** (p<0.01), *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Fig. 3

The effect of wild type SGK3 on KCNA5 was mimicked by constitutively active S419DSGK3 but not by inactive K191NSGK3. A: Representative original tracings showing currents in Xenopus oocytes expressing KCNA5 alone (a), expressing KCNA5 together with wild-type SGK3 (b), expressing KCNA5 together with constitutively active S419DSGK3 (c), or expressing KCNA5 with inactive K191NSGK3 (d). B: Arithmetic means ± SEM (n = 17) of the normalized KCNA5 -peak current at +50 mV in Xenopus laevis oocytes expressing KCNA5 alone (white bar) or expressing KCNA5 together with wild type SGK3 (black bar), with constitutively active S419DSGK3 (dark grey bars), or with inactive K191NSGK3 (light grey bar). ** (p<0.01), *** (p<0.001) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Close modal

Several K+ channels have been shown to be sensitive to Na+/K+ ATPase activity [45]. Thus, the up-regulation of KCNA5 by SGK3 could have been secondary to the known stimulation of Na+/K+ ATPase activity by the kinase [6]. In order to test for a putative role of the Na+/K+ ATPase activity in the up-regulation of KCNA5 channel activity by SGK3, experiments were repeated in the presence of Na+/K+ ATPase inhibitor ouabain (1 mM). Oocytes expressing KCNA5 without or with additional expression of SGK3 were treated with 1 mM ouabain for 10 minutes before measurement and ouabain was superfused during the measurement. As illustrated in Fig. 4, even in the presence of ouabain, coexpression of SGK3 significantly increased IK in Xenopus oocytes expressing KCNA5.

Fig. 4

SGK3 increases the K+ current in ouabain treated KCNA5-expressing Xenopus oocytes. A: Representative original tracings showing currents in ouabain (1 mM) treated Xenopus oocytes expressing KCNA5 alone (a) or expressing KCNA5 together with wild-type SGK3 (b). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 19) of the normalized KCNA5 -peak current at +50 mV in ouabain treated Xenopus oocytes expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. *** (p<0.001) indicates statistically significant difference from ouabain treated oocytes expressing KCNA5 alone (ANOVA-one way).

Fig. 4

SGK3 increases the K+ current in ouabain treated KCNA5-expressing Xenopus oocytes. A: Representative original tracings showing currents in ouabain (1 mM) treated Xenopus oocytes expressing KCNA5 alone (a) or expressing KCNA5 together with wild-type SGK3 (b). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 19) of the normalized KCNA5 -peak current at +50 mV in ouabain treated Xenopus oocytes expressing KCNA5 without (white bar) or with (black bar) additional coexpression of wild-type SGK3. *** (p<0.001) indicates statistically significant difference from ouabain treated oocytes expressing KCNA5 alone (ANOVA-one way).

Close modal

Additional experiments addressed the putative involvement of the ubiquitin ligase Nedd4-2 in the SGK3 sensitive regulation of KCNA5. As illustrated in Fig. 5, coexpression of Nedd4-2 was followed by a marked and significant decrease of IK in Xenopus oocytes expressing KCNA5. The down-regulation of IK was almost completely reversed by the additional coexpression of SGK3.

Fig. 5

SGK3 reverses the decline of K+ current in KCNA5-expressing Xenopus oocytes following coexpression of Nedd4-2. A: Representative original tracings showing currents in Xenopus oocytes expressing KCNA5 alone (a) or expressing KCNA5 with additional coexpression of Nedd4-2 (b) with additional coexpression of constitutively active S419DSGK3 (c), or with additional coexpression of both, S419DSGK3 and Nedd4-2 (d). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 16 - 18) of the normalized KCNA5 -peak current at +50 mV in Xenopus oocytes expressing KCNA5 alone (white bar) or expressing KCNA5 with additional coexpression of Nedd4-2 (light grey bar), with additional coexpression of constitutively active S419DSGK3 (black bar), or with additional coexpression of both, S419DSGK3 and Nedd4-2 (dark grey bar). *** (p<0.001), ** (p<0.01) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Fig. 5

SGK3 reverses the decline of K+ current in KCNA5-expressing Xenopus oocytes following coexpression of Nedd4-2. A: Representative original tracings showing currents in Xenopus oocytes expressing KCNA5 alone (a) or expressing KCNA5 with additional coexpression of Nedd4-2 (b) with additional coexpression of constitutively active S419DSGK3 (c), or with additional coexpression of both, S419DSGK3 and Nedd4-2 (d). Currents were activated by depolarization from -80 to +50 mV in 20 second increments of 10 mV steps from a holding potential of -100 mV. B: Arithmetic means ± SEM (n = 16 - 18) of the normalized KCNA5 -peak current at +50 mV in Xenopus oocytes expressing KCNA5 alone (white bar) or expressing KCNA5 with additional coexpression of Nedd4-2 (light grey bar), with additional coexpression of constitutively active S419DSGK3 (black bar), or with additional coexpression of both, S419DSGK3 and Nedd4-2 (dark grey bar). *** (p<0.001), ** (p<0.01) indicates statistically significant difference from oocytes expressing KCNA5 alone (ANOVA-one way).

Close modal

The present study discloses a positive effect of the serum & glucocorticoid inducible kinase isoform SGK3 on the voltage gated K+ channel KCNA5. Coexpression of SGK3 leads to up-regulation of the voltage gated current in KCNA5 expressing Xenopus oocytes. The effect of wild type SGK3 is mimicked by the constitutively active S419DSGK3, but not by the inactive mutant K191NSGK3. Thus, kinase activity is apparently required for the effect of SGK3 on KCNA5. The observation does not necessarily indicate that SGK3 phosphorylates the KCNA5 channel protein. Instead, SGK3 could exert its effect on KCNA5 by phosphorylating regulators of the channel protein thus indirectly modifying its regulation. Such a regulator is Nedd4-2, an ubiquitin ligase ubiquitinating target proteins thus tagging them for degradation [46]. KCNA5 is a known target of Nedd4-2 [22,23].

The present observations do not allow any safe conclusions about the in vivo significance of SGK3 sensitive KCNA5 regulation. The effect of SGK3 on KCNA5 is small and may not be sufficient to significantly interfere with KCNA5 dependent cellular functions. Moreover, the effect of SGK3 is shared by SGK1 [12,22] which could thus easily replace SGK3. Functions sensitive to K+ channel activity include cell volume regulation [47,48,49]. Cell volume sensitive K+ channels include KCNA5 channels [14,50,51,52,53]. SGK3 sensitive regulation of KCNA5 may in addition foster cell proliferation and survival of tumour cells [13,54,55]. SGK3 has been shown to support survival and proliferation of some tumour cells [56,57,58,59,60,61,62,63]. Further functions of KCNA5 include repolarization of atrial myocardial cells [15,16,17,18], pulmonary arterial vascular dilatation [19,20], and inhibition of insulin release [12]. Clearly, additional experimental evidence is required shedding light on the significance of SGK3-sensitive regulation of KCNA5.

In conclusion, the serum & glucocorticoid inducible kinase isoform SGK3 up-regulates the voltage gated K+ channel KCNA5, an effect possibly contributing to the regulation of cell membrane potential, cell volume and cell proliferation.

The authors acknowledge the meticulous preparation of the manuscript by Lejla Subasic and technical support by Elfriede Faber. This study was supported by the Deutsche Forschungsgemeinschaft, GRK 1302, SFB 773 B4/A1, La 315/13-3, and Open Access Publishing Fund of Tuebingen University. NLU has a fellowship from the Alexander von Humboldt Foundation, Germany.

The authors of this manuscript state that they do not have any conflict of interests and nothing to disclose.

1.
Bhandaru M, Kempe DS, Rotte A, Capuano P, Pathare G, Sopjani M, Alesutan I, Tyan L, Huang DY, Siraskar B, Judenhofer MS, Stange G, Pichler BJ, Biber J, Quintanilla-Martinez L, Wagner CA, Pearce D, Foller M, Lang F: Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase 3. Kidney Int 2011;80:61-67.
2.
Boehmer C, Palmada M, Rajamanickam J, Schniepp R, Amara S, Lang F: Post-translational regulation of EAAT2 function by co-expressed ubiquitin ligase Nedd4-2 is impacted by SGK kinases. J Neurochem 2006;97:911-921.
3.
Bohmer C, Sopjani M, Klaus F, Lindner R, Laufer J, Jeyaraj S, Lang F, Palmada M: The serum and glucocorticoid inducible kinases SGK1-3 stimulate the neutral amino acid transporter SLC6A19. Cell Physiol Biochem 2010;25:723-732.
4.
Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N, Vallon V: (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006;86:1151-1178.
5.
Strutz-Seebohm N, Seebohm G, Korniychuk G, Baltaev R, Ureche O, Striegel M, Lang F: Additive regulation of GluR1 by stargazin and serum- and glucocorticoid-inducible kinase isoform SGK3. Pflugers Arch 2006;452:276-282.
6.
Henke G, Setiawan I, Bohmer C, Lang F: Activation of Na+/K+-ATPase by the serum and glucocorticoid-dependent kinase isoforms. Kidney Blood Press Res 2002;25:370-374.
7.
Schmid E, Bhandaru M, Nurbaeva MK, Yang W, Szteyn K, Russo A, Leibrock C, Tyan L, Pearce D, Shumilina E, Lang F: SGK3 regulates Ca(2+) entry and migration of dendritic cells. Cell Physiol Biochem 2012;30:1423-1435.
8.
Trepiccione F, Capasso G: SGK3: a novel regulator of renal phosphate transport? Kidney Int 2011;80:13-15.
9.
Bohmer C, Palmada M, Kenngott C, Lindner R, Klaus F, Laufer J, Lang F: Regulation of the epithelial calcium channel TRPV6 by the serum and glucocorticoid-inducible kinase isoforms SGK1 and SGK3. FEBS Lett 2007;581:5586-5590.
10.
Pasham V, Rotte A, Bhandaru M, Eichenmuller M, Frohlich H, Mack AF, Bobbala D, Yang W, Pearce D, Lang F: Regulation of gastric acid secretion by the serum and glucocorticoid inducible kinase isoform SGK3. J Gastroenterol 2011;46:305-317.
11.
Maier G, Palmada M, Rajamanickam J, Shumilina E, Bohmer C, Lang F: Upregulation of HERG channels by the serum and glucocorticoid inducible kinase isoform SGK3. Cell Physiol Biochem 2006;18:177-186.
12.
Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, Alexander D, Friedrich B, Wulff P, Kuhl D, Lang F: Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005;54:1090-1099.
13.
Comes N, Bielanska J, Vallejo-Gracia A, Serrano-Albarras A, Marruecos L, Gomez D, Soler C, Condom E, Ramon YCS, Hernandez-Losa J, Ferreres JC, Felipe A: The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. Front Physiol 2013;4:283.
14.
Felipe A, Bielanska J, Comes N, Vallejo A, Roig S, Ramon YCS, Condom E, Hernandez-Losa J, Ferreres JC: Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention. Curr Med Chem 2012;19:661-674.
15.
Bilodeau MT, Trotter BW: Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology. Curr Top Med Chem 2009;9:436-451.
16.
Brendel J, Peukert S: Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr Med Chem Cardiovasc Hematol Agents 2003;1:273-287.
17.
Gonzalez T, David M, Moreno C, Macias A, Valenzuela C: Kv1.5-Kv beta interactions: molecular determinants and pharmacological consequences. Mini Rev Med Chem 2010;10:635-642.
18.
Tamargo J, Caballero R, Gomez R, Delpon E: I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2009;18:399-416.
19.
Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK: Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-578.
20.
Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED: The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007;104:11418-11423.
21.
Lamothe SM, Zhang S: The serum- and glucocorticoid-inducible kinases SGK1 and SGK3 regulate hERG channel expression via ubiquitin ligase Nedd4-2 and GTPase Rab11. J Biol Chem 2013;288:15075-15084.
22.
Boehmer C, Laufer J, Jeyaraj S, Klaus F, Lindner R, Lang F, Palmada M: Modulation of the voltage-gated potassium channel Kv1.5 by the SGK1 protein kinase involves inhibition of channel ubiquitination. Cell Physiol Biochem 2008;22:591-600.
23.
Mia S, Munoz C, Pakladok T, Siraskar G, Voelkl J, Alesutan I, Lang F: Downregulation of Kv1.5 K channels by the AMP-activated protein kinase. Cell Physiol Biochem 2012;30:1039-1050.
24.
Warsi J, Fezai M, Fores M, Elvira B, Lang F: Up-Regulation of Voltage Gated K+ Channels Kv1.3 and Kv1.5 by Protein Kinase PKB/Akt. Cell Physiol Biochem 2015;37:2454-2463.
25.
Kobayashi T, Deak M, Morrice N, Cohen P: Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. Biochem J 1999;344 Pt 1:189-197.
26.
Munoz C, Pakladok T, Almilaji A, Elvira B, Decher N, Shumilina E, Lang F: Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3. Cell Physiol Biochem 2014;33:491-500.
27.
Elvira B, Warsi J, Fezai M, Munoz C, Lang F: SPAK and OSR1 Sensitive Cell Membrane Protein Abundance and Activity of KCNQ1/E1 K+ Channels. Cell Physiol Biochem 2015;37:2032-2042.
28.
Warsi J, Abousaab A, Fezai M, Elvira B, Lang F: Regulation of Voltage Gated K+ Channel KCNE1/KCNQ1 by the Janus Kinase JAK3. Cell Physiol Biochem 2015;37:2476-2485.
29.
Warsi J, Abousaab A, Lang F: Up-Regulation of Excitatory Amino Acid Transporters EAAT1 and EAAT2 by ss-Klotho. Neurosignals 2015;23:59-70.
30.
Fezai M, Ahmed M, Hosseinzadeh Z, Elvira B, Lang F: SPAK and OSR1 Sensitive Kir2.1 K+ Channels. Neurosignals 2015;23:20-33.
31.
Fezai M, Elvira B, Warsi J, Ben-Attia M, Hosseinzadeh Z, Lang F: Up-Regulation of Intestinal Phosphate Transporter NaPi-IIb (SLC34A2) by the Kinases SPAK and OSR1. Kidney Blood Press Res 2015;40:555-564.
32.
Fezai M, Warsi J, Lang F: Regulation of the Na+,Cl- Coupled Creatine Transporter CreaT (SLC6A8) by the Janus Kinase JAK3. Neurosignals 2015;23:11-19.
33.
Ahmed M, Salker MS, Elvira B, Umbach AT, Fakhri H, Saeed AM, Shumilina E, Hosseinzadeh Z, Lang F: SPAK Sensitive Regulation of the Epithelial Na Channel ENaC. Kidney Blood Press Res 2015;40:335-343.
34.
Alesutan I, Voelkl J, Stockigt F, Mia S, Feger M, Primessnig U, Sopjani M, Munoz C, Borst O, Gawaz M, Pieske B, Metzler B, Heinzel F, Schrickel JW, Lang F: AMP-activated protein kinase alpha1 regulates cardiac gap junction protein connexin 43 and electrical remodeling following pressure overload. Cell Physiol Biochem 2015;35:406-418.
35.
Hosseinzadeh Z, Honisch S, Schmid E, Jilani K, Szteyn K, Bhavsar S, Singh Y, Palmada M, Umbach AT, Shumilina E, Lang F: The Role of Janus Kinase 3 in the Regulation of Na(+)/K(+) ATPase under Energy Depletion. Cell Physiol Biochem 2015;36:727-740.
36.
Warsi J, Singh Y, Elvira B, Hosseinzadeh Z, Lang F: Regulation of Large Conductance Voltage-and Ca2+- Activated K+ Channels by the Janus Kinase JAK3. Cell Physiol Biochem 2015;37:297-305.
37.
Almilaji A, Honisch S, Liu G, Elvira B, Ajay SS, Hosseinzadeh Z, Ahmed M, Munoz C, Sopjani M, Lang F: Regulation of the voltage gated K channel Kv1.3 by recombinant human klotho protein. Kidney Blood Press Res 2014;39:609-622.
38.
Almilaji A, Sopjani M, Elvira B, Borras J, Dermaku-Sopjani M, Munoz C, Warsi J, Lang UE, Lang F: Upregulation of the creatine transporter Slc6A8 by Klotho. Kidney Blood Press Res 2014;39:516-525.
39.
Fezai M, Elvira B, Borras J, Ben-Attia M, Hoseinzadeh Z, Lang F: Negative regulation of the creatine transporter SLC6A8 by SPAK and OSR1. Kidney Blood Press Res 2014;39:546-554.
40.
Warsi J, Dong L, Elvira B, Salker MS, Shumilina E, Hosseinzadeh Z, Lang F: SPAK dependent regulation of peptide transporters PEPT1 and PEPT2. Kidney Blood Press Res 2014;39:388-398.
41.
Warsi J, Elvira B, Bissinger R, Shumilina E, Hosseinzadeh Z, Lang F: Downregulation of peptide transporters PEPT1 and PEPT2 by oxidative stress responsive kinase OSR1. Kidney Blood Press Res 2014;39:591-599.
42.
Warsi J, Hosseinzadeh Z, Elvira B, Bissinger R, Shumilina E, Lang F: Regulation of ClC-2 activity by SPAK and OSR1. Kidney Blood Press Res 2014;39:378-387.
43.
Dermaku-Sopjani M, Almilaji A, Pakladok T, Munoz C, Hosseinzadeh Z, Blecua M, Sopjani M, Lang F: Down-regulation of the Na+-coupled phosphate transporter NaPi-IIa by AMP-activated protein kinase. Kidney Blood Press Res 2013;37:547-556.
44.
Elvira B, Munoz C, Borras J, Chen H, Warsi J, Ajay SS, Shumilina E, Lang F: SPAK and OSR1 dependent down-regulation of murine renal outer medullary K channel ROMK1. Kidney Blood Press Res 2014;39:353-360.
45.
Lang F, Rehwald W: Potassium channels in renal epithelial transport regulation. Physiol Rev 1992;72:1-32.
46.
Rizzo F, Staub O: NEDD4-2 and salt-sensitive hypertension. Curr Opin Nephrol Hypertens 2015;24:111-116.
47.
Hoffmann EK: Ion channels involved in cell volume regulation: effects on migration, proliferation, and programmed cell death in non adherent EAT cells and adherent ELA cells. Cell Physiol Biochem 2011;28:1061-1078.
48.
Hoffmann EK, Lambert IH, Pedersen SF: Physiology of cell volume regulation in vertebrates. Physiol Rev 2009;89:193-277.
49.
Lang F: Mechanisms and significance of cell volume regulation. J Am Coll Nutr 2007;26:613S-623S.
50.
Barfield JP, Yeung CH, Cooper TG: Characterization of potassium channels involved in volume regulation of human spermatozoa. Mol Hum Reprod 2005;11:891-897.
51.
Barfield JP, Yeung CH, Cooper TG: The effects of putative K+ channel blockers on volume regulation of murine spermatozoa. Biol Reprod 2005;72:1275-1281.
52.
Felipe A, Snyders DJ, Deal KK, Tamkun MM: Influence of cloned voltage-gated K+ channel expression on alanine transport, Rb+ uptake, and cell volume. Am J Physiol 1993;265:C1230-1238.
53.
Yeung CH, Cooper TG: Potassium channels involved in human sperm volume regulation-quantitative studies at the protein and mRNA levels. Mol Reprod Dev 2008;75:659-668.
54.
Leanza L, O'Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabo I: Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des 2014;20:189-200.
55.
Leanza L, Zoratti M, Gulbins E, Szabo I: Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr Med Chem 2012;19:5394-5404.
56.
Bruhn MA, Pearson RB, Hannan RD, Sheppard KE: Second AKT: the rise of SGK in cancer signalling. Growth Factors 2010;28:394-408.
57.
Gasser JA, Inuzuka H, Lau AW, Wei W, Beroukhim R, Toker A: SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell 2014;56:595-607.
58.
Hou M, Lai Y, He S, He W, Shen H, Ke Z: SGK3 (CISK) may induce tumor angiogenesis (Hypothesis). Oncol Lett 2015;10:23-26.
59.
Liu H, Li C, Shen C, Yin F, Wang K, Liu Y, Zheng B, Zhang W, Hou X, Chen X, Wu J, Wang X, Zhong C, Zhang J, Shi H, Ai J, Zhao S: MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3. J Neurooncol 2015;122:431-439.
60.
Liu M, Chen L, Chan TH, Wang J, Li Y, Li Y, Zeng TT, Yuan YF, Guan XY: Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. Hepatology 2012;55:1754-1765.
61.
Wang Y, Xu W, Zhou D, Neckers L, Chen S: Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex. J Biol Chem 2014;289:4815-4826.
62.
Wang Y, Zhou D, Chen S: SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1. Mol Endocrinol 2014;28:935-948.
63.
Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S: SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol 2011;25:72-82.
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.